Literature DB >> 15793148

Synergistic activities of fluconazole and voriconazole with terbinafine against four Candida species determined by checkerboard, time-kill, and Etest methods.

Emilia Cantón1, Javier Pemán, Miguel Gobernado, Angel Viudes, Ana Espinel-Ingroff.   

Abstract

The in vitro activities of fluconazole or voriconazole plus terbinafine were evaluated against 20 Candida isolates by the checkerboard, time-kill, and Etest methods. Synergism (C. albicans, C. glabrata, and C. tropicalis) and indifference (C. krusei) were observed. Correlation among methods was good. The Etest is a suitable method to determine drug interactions.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15793148      PMCID： PMC1068629          DOI： 10.1128/AAC.49.4.1593-1596.2005

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  17 in total

1.  In vitro activities of pentamidine, pyrimethamine, trimethoprim, and sulfonamides against Aspergillus species.

Authors:  Javier Afeltra; Jacques F G M Meis; Roxana G Vitale; Johan W Mouton; Paul E Verweij
Journal:  Antimicrob Agents Chemother       Date:  2002-06       Impact factor: 5.191

2.  In vitro activities of terbinafine in combination with fluconazole, itraconazole, voriconazole, and posaconazole against clinical isolates of Candida glabrata with decreased susceptibility to azoles.

Authors:  Sofia Perea; Gloria Gonzalez; Annette W Fothergill; Deanna A Sutton; Michael G Rinaldi
Journal:  J Clin Microbiol       Date:  2002-05       Impact factor: 5.948

3.  In-vitro interaction of terbinafine with amphotericin B, fluconazole and itraconazole against clinical isolates of Candida albicans.

Authors:  F Barchiesi; L F Di Francesco; P Compagnucci; D Arzeni; A Giacometti; G Scalise
Journal:  J Antimicrob Chemother       Date:  1998-01       Impact factor: 5.790

4.  Synergism of voriconazole and terbinafine against Candida albicans isolates from human immunodeficiency virus-infected patients with oropharyngeal candidiasis.

Authors:  M Weig; F M Müller
Journal:  Antimicrob Agents Chemother       Date:  2001-03       Impact factor: 5.191

Review 5.  Review of the safety and efficacy of voriconazole.

Authors:  Holly L Hoffman; R Chris Rathbun
Journal:  Expert Opin Investig Drugs       Date:  2002-03       Impact factor: 6.206

6.  Antifungal activity of ibuprofen alone and in combination with fluconazole against Candida species.

Authors:  Cidália Pina-Vaz; Filipe Sansonetty; Acácio G Rodrigues; J Martinez-DE-Oliveira; António F Fonseca; Per-Anders Mårdh
Journal:  J Med Microbiol       Date:  2000-09       Impact factor: 2.472

7.  Comparative efficacies of terbinafine and fluconazole in treatment of experimental coccidioidal meningitis in a rabbit model.

Authors:  K N Sorensen; R A Sobel; K V Clemons; L Calderon; K J Howell; P R Irani; D Pappagianis; P L Williams; D A Stevens
Journal:  Antimicrob Agents Chemother       Date:  2000-11       Impact factor: 5.191

8.  Pharmacokinetics and safety of voriconazole following intravenous- to oral-dose escalation regimens.

Authors:  L Purkins; N Wood; P Ghahramani; K Greenhalgh; M J Allen; D Kleinermans
Journal:  Antimicrob Agents Chemother       Date:  2002-08       Impact factor: 5.191

9.  In vivo pharmacokinetics and pharmacodynamics of a new triazole, voriconazole, in a murine candidiasis model.

Authors:  D Andes; K Marchillo; T Stamstad; R Conklin
Journal:  Antimicrob Agents Chemother       Date:  2003-10       Impact factor: 5.191

Review 10.  Fluconazole: optimized antifungal therapy based on pharmacokinetics.

Authors:  G Silling
Journal:  Mycoses       Date:  2002       Impact factor: 4.377
View more
  17 in total

1.  Multilaboratory testing of two-drug combinations of antifungals against Candida albicans, Candida glabrata, and Candida parapsilosis.

Authors:  Vishnu Chaturvedi; Rama Ramani; David Andes; Daniel J Diekema; Michael A Pfaller; Mahmoud A Ghannoum; Cindy Knapp; Shawn R Lockhart; Luis Ostrosky-Zeichner; Thomas J Walsh; Karen Marchillo; Shawn Messer; Amanda R Welshenbaugh; Cara Bastulli; Noreen Iqbal; Victor L Paetznick; Jose Rodriguez; Tin Sein
Journal:  Antimicrob Agents Chemother       Date:  2011-01-31       Impact factor: 5.191

Review 2.  Pharmacokinetics of antifungal drugs: practical implications for optimized treatment of patients.

Authors:  Romuald Bellmann; Piotr Smuszkiewicz
Journal:  Infection       Date:  2017-07-12       Impact factor: 3.553

3.  Use of Antifungal Combination Therapy: Agents, Order, and Timing.

Authors:  Melissa D Johnson; John R Perfect
Journal:  Curr Fungal Infect Rep       Date:  2010-05-01

4.  The Antifungal and Synergistic Effect of Bisphosphonates in Cryptococcus.

Authors:  Aidan Kane; Leona Campbell; Diana Ky; David Hibbs; Dee Carter
Journal:  Antimicrob Agents Chemother       Date:  2021-01-20       Impact factor: 5.191

5.  Spondylodiscitis caused by Candida krusei: case report and susceptibility patterns.

Authors:  Javier Pemán; Isidro Jarque; María Bosch; Emilia Cantón; Miguel Salavert; Rosario de Llanos; Araceli Molina
Journal:  J Clin Microbiol       Date:  2006-05       Impact factor: 5.948

6.  Antifungal Efficacy of an Intravenous Formulation Containing Monomeric Amphotericin B, 5-Fluorocytosine, and Saline for Sodium Supplementation.

Authors:  Celeste Alvarez; David R Andes; Jeong Yeon Kang; Carmen Krug; Glen S Kwon
Journal:  Pharm Res       Date:  2017-02-15       Impact factor: 4.200

Review 7.  Voriconazole : a review of its use in the management of invasive fungal infections.

Authors:  Lesley J Scott; Dene Simpson
Journal:  Drugs       Date:  2007       Impact factor: 9.546

8.  Head-to-head comparison of inhibitory and fungicidal activities of fluconazole, itraconazole, voriconazole, posaconazole, and isavuconazole against clinical isolates of Trichosporon asahii.

Authors:  Gulsen Hazirolan; Emilia Canton; Selma Sahin; Sevtap Arikan-Akdagli
Journal:  Antimicrob Agents Chemother       Date:  2013-07-22       Impact factor: 5.191

9.  Measurement of voriconazole activity against Candida albicans, C. glabrata, and C. parapsilosis isolates using time-kill methods validated by high-performance liquid chromatography.

Authors:  Yanjun Li; M Hong Nguyen; Hartmut Derendorf; Shaoji Cheng; Cornelius J Clancy
Journal:  Antimicrob Agents Chemother       Date:  2007-05-21       Impact factor: 5.191

10.  Multilaboratory testing of antifungal combinations against a quality control isolate of Candida krusei.

Authors:  Vishnu Chaturvedi; Rama Ramani; Mahmoud A Ghannoum; Scott B Killian; Nicole Holliday; Cindy Knapp; Luis Ostrosky-Zeichner; Shawn A Messer; Michael A Pfaller; Naureen J Iqbal; Beth A Arthington-Skaggs; Jose A Vazquez; Tin Sein; John H Rex; Thomas J Walsh
Journal:  Antimicrob Agents Chemother       Date:  2008-01-28       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.